Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-24 @ 2:38 PM
Ignite Modification Date: 2025-12-25 @ 1:10 PM
NCT ID: NCT04256759
Description: The adverse event definition used in this study was: An untoward or undesirable experience associated with the use of a medical product (i.e. drug, device, biologic) in a patient or research subject. Adverse events were collected through specific questioning and physical examinations.
Frequency Threshold: 0
Time Frame: Adverse events were collected from the time of informed consent through study completion, approximately 22 weeks.
Study: NCT04256759
Study Brief: Dupilumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
Dupilumab Subcutaneous (SC) dupilumab selected for this study was 300 mg every 2 weeks for 18 weeks. Dupilumab 300Mg Solution for Injection: Subcutaneous (SC) dupilumab selected for this study was 300 mg every 2 weeks for 18 weeks. 0 None 0 9 0 9 View
Serious Events(If Any):
Other Events(If Any):